Bionoid Pharma, Inc.
BINP · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $3 | $17 | $13 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $3 | $17 | $14 |
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | – | 100% | -290.7% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | 559% | -1,487.5% |
| EBITDA | -$0 | -$0 | $1 | -$0 |
| % Margin | – | – | -2,689.1% | -86.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | 611.2% | -1,677.4% |
| EPS Diluted | -0.004 | -0.005 | -0.002 | -0.003 |
| % Growth | 15.2% | -206.7% | 55.9% | – |
| Operating Cash Flow | – | – | – | – |
| Capital Expenditures | – | – | – | – |
| Free Cash Flow | – | – | – | – |